Mosaic HIV-1 envelopes to induce ADCC responses

Abstract

The invention is directed to mosaic HIV-1 envelopes, and methods of using the same to induce ADCC responses.

Description

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Nov. 16, 2018, is named 2933311-038-WO1_SL.txt and is 380,186 bytes in size.

FIELD OF THE INVENTION

The invention is directed to mosaic HIV-1 envelopes, and methods of using the same to induce ADCC responses.

BACKGROUND OF THE INVENTION

Antibody (Ab)—dependent cellular cytotoxicity (ADCC) plays a role in vaccine-induced protection from HIV-1. See Bradley et al. (2017) Nature Communications, vol. 8, p. 1571; DOI 10.1038/ncomms15711.

SUMMARY OF THE INVENTION

In some aspects the invention provides new mosaic HIV-1 envelope designs, selection of HIV-1 envelopes and combinations thereof. In some aspects the invention is directed to methods of using these envelopes to induce antibody responses. In some aspects, these antibody responses include without limitation protective antibody responses, T-cells responses, or the combination thereof. Without being bound by theory, in some embodiments, these protective responses are associated with ADCC activity.

In certain embodiments, the invention provides a new strategy to decrease number of Envs needed while retraining good epitope diversity coverage—these new envelopes are referred to as “ADCC structural mosaics.”

In some aspects the invention provides immunogenic compositions comprising any one of the envelopes listed in Table 1, for example as nucleic acids, proteins or combination thereof. In some embodiments these immunogens are designed to as gp120 envelopes. In some embodiments these immunogens are designed as immunogens which do not have closed envelope trimer structure. The invention provides that sets are complementary. They are solved simultaneously or serially. In some embodiments, these sets are serial. In some embodiments, the first members of sets can be used alone. In certain embodiments, while the second or subsequent member is complementary, in certain embodiments, is not to be used alone

In certain aspects, the invention provides an immunogenic composition comprising a recombinant polypeptide of any one of the envelopes listed in Table 1 or FIG. 2, a nucleic acid encoding any one of the envelopes listed in Table 1 or FIG. 2, or a combination thereof. Non-limiting selections and rationale for selections and combinations are described in Example 1, and FIG. 1. In non-limiting embodiments, the recombinant envelope is ADCC-StrMos.B. 1+1.1Δ11gp120. In non-limiting embodiments, the recombinant envelope is ADCC-StrNat.B1Δ11gp120.

In certain embodiments, the composition comprises a recombinant envelopes in group GP502, ADCC-StrMos.B.1+1.1Δ11gp120 (SEQ ID NO: 12) and ADCC-StrMos.B.1+1.2Δ11gp120 (SEQ ID NO: 13), or a nucleic acids encoding these.

In certain embodiments, the composition comprises a recombinant envelopes in group GP503, ADCC-StrNat.B1Δ11gp120 (SEQ ID NO: 14) and ADCC-StrNat.B5Δ11gp120 (SEQ ID NO: 15), or nucleic acids encoding these.

In certain embodiments, wherein the composition comprises a recombinant envelope envelopes in group GP504, ADCC-StrNat.B1Δ11gp120 (SEQ ID NO: 14), ADCC-StrNat.B2Δ11gp120 (SEQ ID NO: 116), ADCC-StrNat.B3Δ11gp120 (SEQ ID NO: 17), ADCC-StrNat.B4Δ11gp120 (SEQ ID NO: 18), and ADCC-StrNat.B5Δ11gp120 (SEQ ID NO: 15), or nucleic acids encoding these.

In certain embodiments, the composition comprises recombinant envelopes in group GP505, ADCC-StrMos.M.3+2.4 Δ11gp120 (SEQ ID NO: 19) and ADCC-StrMos.M.3+2.5 Δ11gp120 (SEQ ID NO: 20), or nucleic acids encoding these.

In certain embodiments, the composition comprises a recombinant envelopes in group GP506, ADCC-StrMos.B.1+1.1Δ11gp120 (SEQ ID NO: 12), ADCC.StrMos.C.1+1.1Δ11gp120 (SEQ ID NO:21) and ADCC.StrMos.AE.1+1.1Δ11gp120 (SEQ ID NO: 22), or nucleic acids encoding these.

In certain aspects, the invention provides nucleic acid enocoding any one of the recombinant envelopes in the preceding claims wherein the nucleic acid is a modified mRNA.

In certain aspects, the invention provides nucleic acid enocoding any one of the recombinant envelopes in the preceding claims wherein the nucleic acid is operably linked to a promoter.

In certain embodiments, the compositions further comprise an adjuvant, and/or a carrier.

In certain aspects, the invention provides methods of inducing an immune response in a subject comprising administering to the subject an amount of the composition of the invention an amount sufficient to effect such induction. In certain embodiments the methods further comprise administering an adjuvant.

In certain embodiments the compositions are administered as a prime.

In certain embodiments the compositions are administered as a boost or multiple boosts.

In certain aspects the invention provides an isolated and purified recombinant envelope listed in Table 1 or FIG. 2, or a nucleic acid encoding the same.

In certain embodiments, the invention provides compositions comprising recombinant envelopes from GP502, ADCC-StrMos.B.1+1.1 and ADCC-StrMos.B.1+1.2, or a nucleic acids encoding these. In certain embodiments, the invention provides compositions comprising recombinant envelopes in group GP506, ADCC-StrMos.B.1+1.1, ADCC.StrMos.C.1+1.1Δ11 and ADCC.StrMos.AE.1+1.1, or nucleic acids encoding these. In certain embodiments the nucleic acids are mRNAs.

The invention provides compositions immunogens and methods for inducing antibodies to the HIV-1 envelope, wherein in some embodiments, the compositions induce protective responses which in some embodiments are associated with ADCC activity.

In certain embodiments, the compositions comprise nucleic acid, as DNA and/or RNA, or proteins immunogens, for example either alone or in any combination. In certain embodiments, the methods comprise genetic, as DNA and/or RNA, immunization, for example alone or in combination with envelope protein(s). The method and/or compositions, whether comprising nucleic acids or recombinant proteins can further comprise any suitable adjuvant. In certain embodiments the invention provides that the immunogens are administered as stabilized mRNAs. See e.g. Pardi et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature, 2017; DOI: 10.1038/nature21428.

In certain embodiments the nucleic acid encoding an envelope is operably linked to a promoter inserted an expression vector. In certain aspects the compositions comprise a suitable carrier. In certain aspects the compositions comprise a suitable adjuvant.

In certain embodiments the induced immune response includes induction of antibodies, including but not limited to ADCC responses, autologous and/or cross-reactive (broadly) neutralizing antibodies against HIV-1 envelope. Various assays that analyze whether an immunogenic composition induces an immune response, and the type of antibodies induced are known in the art and are also described herein. Methods and assays to determine correlates of protection are known in the art.

In certain aspects the invention provides an expression vector comprising any of the nucleic acid sequences of the invention, wherein the nucleic acid is operably linked to a promoter. In certain aspects the invention provides an expression vector comprising a nucleic acid sequence encoding any of the polypeptides of the invention, wherein the nucleic acid is operably linked to a promoter. In certain embodiments, the nucleic acids are codon optimized for expression in a mammalian cell, in vivo or in vitro. In certain aspects the invention provides nucleic acids comprising any one of the nucleic acid sequences of invention. In certain aspects the invention provides nucleic acids consisting essentially of any one of the nucleic acid sequences of invention. In certain aspects the invention provides nucleic acids consisting of any one of the nucleic acid sequences of invention. In certain embodiments the nucleic acid of the invention, is operably linked to a promoter and is inserted in an expression vector. In certain aspects the invention provides an immunogenic composition comprising the expression vector.

In certain aspects the invention provides a composition comprising at least one of the nucleic acid sequences of the invention. In certain aspects the invention provides a composition comprising any one of the nucleic acid sequences of invention. In certain aspects the invention provides a composition comprising at least one nucleic acid sequence encoding any one of the polypeptides of the invention.

The envelope used in the compositions and methods of the invention can be in any suitable form: a gp160, gp150, gp145, any suitable form of a trimer, for example but not limited to SOSIP trimers, gp140 (including but not limited to gp140C, gp140CF, gp140CFI), gp120, gp41, N-terminal deletion variants (e.g. delta 11 deletions) as described herein, cleavage resistant variants, or codon optimized sequences thereof.

The polypeptide described herein can be a polypeptide comprising any one of the polypeptides described herein. The polypeptide can be a polypeptide consisting essentially of any one of the polypeptides described herein. The polypeptide described herein can be a polypeptide consisting of any one of the polypeptides described herein. In certain embodiments, the polypeptide is recombinantly produced. In certain embodiments, the polypeptides and nucleic acids of the invention are suitable for use as an immunogen, for example to be administered in a human subject.

The envelope used in the compositions and methods of the invention can be a gp160, gp150, gp145, gp140, gp120, gp41, N-terminal deletion variants as described herein, cleavage resistant variants as described herein, or codon optimized sequences thereof. In certain embodiments the composition comprises envelopes as trimers. In certain embodiments, envelope proteins are multimerized, for example envelopes are attached to a particle such that multiple copies are attached and the multimerized envelope is prepared and formulated for immunization in a human. In certain embodiments, the compositions comprise envelopes, as particulate, high-density array on liposomes or other particles, for example but not limited to nanoparticles. In some embodiments, the envelopes are in a well ordered, near native like or closed conformation.

In certain embodiments, where the nucleic acids are operably linked to a promoter and inserted in a vector, wherein the vector is any suitable vector. Non-limiting examples, include, the VSV, replicating rAdenovirus type 4, MVA, Chimp adenovirus vectors, pox vectors, and the like. In certain embodiments, the nucleic acids are administered in NanoTaxi block polymer nanospheres. In certain embodiments, the composition and methods comprise an adjuvant. Non-limiting examples include, 3M052, AS01 B, AS01 E, Gla/SE, alum, Poly I poly C (in any form, including but not limited to PolyIC/long chain (LC)), TLR agonists, TLR7/8 and 9 agonists, or a combination of TLR7/8 and TLR9 agonists (see Moody et al. (2014) J. Virol. March 2014 vol. 88 no. 6 3329-3339), or any other adjuvant. Non-limiting examples of TLR7/8 agonist include TLR7/8 ligands, Gardiquimod, Imiquimod and R848 (resiquimod). A non-limiting embodiment of a combination of TLR7/8 and TLR9 agonist comprises R848 and oCpG in STS (see Moody et al. (2014) J. Virol. March 2014 vol. 88 no. 6 3329-3339).

In certain aspects, the invention provides a kit comprising a combination/selection of immunogens, for example but not limited to combination of immunogens as described herein.

BRIEF DESCRIPTION OF THE FIGURES

FIGS. 1A-1K show embodiments of envelopes of the invention. SEQ ID Nos: 1-11 are the listed amino acid sequences. SEQ ID Nos: 12-22 the amino acid sequence without the leader peptide. These are envelopes used in the animal study described in Ex. 4, and corresponding figures. FIG. 1A illustrates SEQ ID NO. 1. FIG. 1B illustrates SEQ ID NO. 2. FIG. 1C illustrates SEQ ID NO. 3. FIG. 1D illustrates SEQ ID NO. 4. FIG. 1E illustrates SEQ ID NO. 5. FIG. 1F illustrates SEQ ID NO. 6. FIG. 1G illustrates SEQ ID NO. 7. FIG. 1H illustrates SEQ ID NO. 8. FIG. 1I illustrates SEQ ID NO. 9. FIG. 1J illustrates SEQ ID NO. 10. FIG. 1K illustrates SEQ ID NO. 11.

FIGS. 2A-2S show embodiments of envelopes of the invention. SEQ ID NOS. 23-35 and 32-37, respectively, in order of appearance.

FIG. 3-3S show embodiments of envelopes of the invention. Underlined are amino acids in the N-terminus which are deleted to generate deltaN variants. SEQ ID NOS. 23-35, 32-35 and 38-39, respectively, in order of appearance.

FIGS. 4A-40 show embodiments of envelopes of the invention. Delta N variants of a selection of the sequences in FIG. 3. SEQ ID NOS. 1-3, 40, 6-7, 4, 41-44, 11, 45, 8 and 46, respectively, in order of appearance.

FIGS. 5A-50 show embodiments of envelopes of the invention. Non-limiting embodiments of codon optimized nucleic acid sequences. SEQ ID NOS. 47-61, respectively, in order of appearance.

FIGS. 6A-60 show embodiments of envelopes of the invention. These sequences are a translation of the sequences of FIG. 5. SEQ ID NOS. 1-3, 40, 6-7, 4, 41-44, 11, 45, 8 and 46, respectively, in order of appearance.

FIG. 7A shows a table adapted from an IAS presentation on Jul. 24, 2017 in Paris, France, entitled “Evaluation of lead HIV-1 vaccine regimen in APPROACH: Phase 1/2a study testing heterologous prime boost regimens using mosaic Ad26 and MVA vectors combined with Env protein” and an IAS presentation on Jul. 25, 2017 entitled “The Ad26/Ad26+gp140 HIV Vaccine Regimen Provided Sigificant Protection against SHIV_SF162P3 Challenges in NHP (study 13-19*). After completion of TRAVERSE, proof of concept: HPX2008/HVTN 705. Correlates: Elisa, Elispot, ADCP: not tier 2 bNAbs. FIG. 7B shows that boosting RV144 participants in RV305 clinical trial resulted in a new V2 recognition footprints. FIG. 7B discloses SEQ ID NOS 62-69, respectively, in order of appearance. FIG. 7C shows that the V2 region that is highly variable, including V2 contacts (underlined in red). FIG. 7C discloses SEQ ID NOS 70-122, respectively, in order of appearance.

FIG. 8 is a schematic showing coverage of V2 epitopes and CH59 signatures in the B Glade by different epitope options. V2 ADCC antibody contact regions, within contact CH59 associations, positions 161, 166, and 168.

FIG. 9 is a schematic showing that V2 Ab CH59 has sensitivity signatures in the A32 contacts. These sensitivity signatures are also enriched in CRF01. Without being bound by theory, these A32 contacts enable V2 epitope exposure, similarly to H375 enabling A32 exposure in CRF01.

FIG. 10 is a schematic of the A32 maps to the C1-C2 regions of gp120. See also, Tolbert W D, Gohain N at al.(2016) Structure, 2016, 24(5):697-709; Gohain N, Tolbert at al. (2015) J Virol. 89(17):8840-54; and Acharya P, Tolbert at al. (2014) J Virol. 88(21):12895-906. FIG. 10 discloses SEQ ID NOS 123-134, respectively, in order of appearance.

FIG. 11 shows structures of the A32 epitope. To incorporate structure, a single monomer from a CD4 bound open trimer was used.

FIG. 12 shows a protein ribbon structure of the A32 epitope. A new CD4 bound open structure is shown in green, with a higher resolution, and more structural features. A similar trace in red is shown, but with less detail.

FIG. 13 shows a model of an HIV-1 envelope used for design of structural mosaics. Local regions: 8 closest amino acids defined for each amino acid in the structure: “local spheres.” Any given amino acid is involved in many local spheres. Genetic algorithm: Maximize 3 dimensional potential epitope (=local sphere) coverage, choosing from among vast pools in silico recombinants that resemble natural proteins. Genetic algorithm solves for immunogen proteins that in combination yield the best population coverage of all local spheres in the structure. The whole structure is solved simultaneously, not just the A32 epitope in isolation. Sets are complementary, valency=2, 3, 5, or 6.

FIG. 14 shows a schematic of a signature analysis, A32 contacts.

FIG. 15 shows a schematic of variable position in the A32 contacts and vaccine coverage. Variable positions in the A32 contact surface.—coverage of different clades by different vaccine options. The green text represents B Glade consensus amino acids. The pink text represents other amino acids in the vaccine. The coverage of A32 contact diversity is improved considerably by going to an M group vaccine, even with the B Glade.

FIG. 16 shows amino acids sequences, where V2 regions are “woven” in, no structures, unalignable. FIG. 16 discloses SEQ ID NOS 135-144, respectively, in order of appearance.

FIG. 17A shows a schematic where the V3 loop can be fixed to prevent cleavage during recombinant production for example, by taking GPGR/S/K and making it into GPGQ (SEQ ID NO: 179), and also taking the Ala after the R/S/K and making it into T to prevent cleavage during recombinant production. In some embodiments, protease inhibitors also work, other mutations can also be made to reduce or eliminate the cleavage of the protein during recombinant production. FIG. 17A discloses SEQ ID NOS 145-156, respectively, in order of appearance. FIG. 17B show embodiments of V3 sequences of ADCC mosaic envelopes of the invention. FIG. 17B discloses SEQ ID NOS 157-170, respectively, in order of appearance.

FIG. 17C shows embodiments of V3 sequences of the designated envelopes. “mutC” sequences have amino acid changes designed to reduce cleavage of the V3 loop during recombinant expression. FIG. 17C discloses SEQ ID NOS 171-173, 171, 174-175, 171 and 176-178, respectively, in order of appearance.

FIG. 18A shows a design of an animal study of ADCC mosaics versus natural Env gp120s. FIG. 18B shows immunization timeline for an animal study. In some embodiments, Gr. XX is Gr. 502, Gr. 503, Gr. 504, Gr. 505, or Gr. 506.

FIG. 19 shows the gp120 average score for the entire gp120 panel (all the members of the panel listed on the next slide). Compares the key groups with each other. Mean binding of guinea pig sera from the indicated groups (GP502-GP506) to eight different gp120's from multiple clades was determined by indirect ELISA at pre-bleed and post bleeds 2 and 4. Plates were coated with protein at 2 ug/ml and sera were tittered in 3 fold serial dilutions. Each titration was expressed as the log of area under the curve (Log AUC). Each symbol represents the average data for an individual animal within each group of six animals. Higher Log AUC represents greater binding to the test protein.

FIG. 20 shows the reactivity of postbleed 2 of the indicated groups for the entire gp120 panel. Compares the key groups with each other to give a visual of how the groups did on each env. Binding of post bleed 2 guinea pig sera from the indicated groups (GP502-GP506) to gp120 was determined by indirect ELISA. Plates were coated with protein at 2 ug/ml and sera were tittered in 3 fold serial dilutions. Each titration was expressed as the log of area under the curve (Log AUC). Each symbol represents an individual animal within each group of six animals. Higher Log AUC represents greater binding to the test protein.

FIG. 21 shows the reactivity of postbleed 4 of the indicated groups for the entire gp120 panel. Compares the key groups with each other to give a visual of how the groups did on each env. Binding of post bleed 4 guinea pig sera from the indicated groups (GP502-GP506) to gp120 was determined by indirect ELISA. Plates were coated with protein at 2 ug/ml and sera were tittered in 3 fold serial dilutions. Each titration was expressed as the log of area under the curve (Log AUC). Each symbol represents an individual animal within each group of six animals. Higher Log AUC represents greater binding to the test protein.

FIG. 22 shows the gp140 average score for the entire gp140 panel (all the members of the panel listed on the next slide). Compares the key groups with each other. Mean binding of guinea pig sera from the indicated groups (GP502-GP506) to eight different gp140's from multiple clades was determined by indirect ELISA at pre-bleed and post bleeds 2 and 4. Plates were coated with protein at 2 ug/ml and sera were tittered in 3 fold serial dilutions. Each titration was expressed as the log of area under the curve (Log AUC). Each symbol represents the average data for an individual animal within each group of six animals. Higher Log AUC represents greater binding to the test protein.

FIG. 23 shows the reactivity of postbleed 2 of the indicated groups for the entire gp140 panel. Compares the key groups with each other to give a visual of how the groups did on each env. Binding of post bleed 2 guinea pig sera from the indicated groups (GP502-GP506) to gp140 was determined by indirect ELISA. Plates were coated with protein at 2 ug/ml and sera were tittered in 3 fold serial dilutions. Each titration was expressed as the log of area under the curve (Log AUC). Each symbol represents an individual animal within each group of six animals. Higher Log AUC represents greater binding to the test protein.

FIG. 24 shows reactivity of postbleed 4 of the indicated groups for the entire gp140 panel. Compares the key groups with each other to give a visual of how the groups did on each env. Binding of post bleed 4 guinea pig sera from the indicated groups (GP502-GP506) to gp140 was determined by indirect ELISA. Plates were coated with protein at 2 ug/ml and sera were tittered in 3 fold serial dilutions. Each titration was expressed as the log of area under the curve (Log AUC). Each symbol represents an individual animal within each group of six animals. Higher Log AUC represents greater binding to the test protein.

FIG. 25 shows the gp70 V1V2 average score for the entire V1V2 panel (all the members of the panel listed on the next slide). Compares the key groups with each other. Mean binding of guinea pig sera from the indicated groups (GP502-GP506) to sixteen different V1V2 proteins from multiple clades was determined by indirect ELISA at pre-bleed and post bleeds 2 and 4. Plates were coated with protein at 2 ug/ml and sera were tittered in 3 fold serial dilutions. Each titration was expressed as the log of area under the curve (Log AUC). Each symbol represents the average data for an individual animal within each group of six animals. Higher Log AUC represents greater binding to the test protein.

FIG. 26 shows the reactivity of postbleed 2 of the indicated groups for the entire V1V2 panel post bleed 2. Compares the key groups with each other to give a visual of how the groups did on each env. Binding of post bleed 2 guinea pig sera from the indicated groups (GP502-GP506) to V1V2 protein was determined by indirect ELISA. Plates were coated with protein at 2 ug/ml and sera were tittered in 3 fold serial dilutions. Each titration was expressed as the log of area under the curve (Log AUC). Each symbol represents an individual animal within each group of six animals. Higher Log AUC represents greater binding to the test protein.

FIG. 27 shows the reactivity of the indicated groups for the entire V1V2 panel post bleed 4. Compares the key groups with each other to give a visual of how the groups did on each env. Binding of post bleed 4 guinea pig sera from the indicated groups (GP502-GP506) to V1V2 protein was determined by indirect ELISA. Plates were coated with protein at 2 ug/ml and sera were tittered in 3 fold serial dilutions. Each titration was expressed as the log of area under the curve (Log AUC). Each symbol represents an individual animal within each group of six animals. Higher Log AUC represents greater binding to the test protein.

FIG. 28A-28C shows the reactivity of the indicated groups for some mutants that knockout either A32, or C11 epitope ADCC binding. Binding of guinea pig sera from the indicated groups (GP502 and GP503) to wild type A244 gp120 and two mutant forms was determined by indirect ELISA. Plates were coated with protein at 2 ug/ml and sera were tittered in 3 fold serial dilutions. Each titration was expressed as the log of area under the curve (Log AUC). Each symbol represents an individual animal within each group of six animals. Higher Log AUC represents greater binding to the test protein.

FIG. 29A-29F shows the blocking assays average score for the entire panel of blocking assays (all the assays of the blocking panel listed on the next figure). Compares the key groups with each other. Mean blocking activity of post bleed guinea pig sera from the indicated groups (GP502-GP506) was measured by ELISA. The mean was calculated from the results of blocking across seven different antibody specificities. Plates were coated with protein at 2 ug/ml. Sera were added at a 1:50 dilution, washed and a biotinylated epitope specific monoclonal antibody was added at an amount equivalent to the EC50. Reduction in binding of the biotinylated antibody was compared to a full binding control and expressed as % Blocking. Each symbol represents an individual animal within each group of six animals. Higher % Blocking suggests greater binding of the sera to specific epitopes on the test protein. FIGS. 30-XX show mean serum blocking activity of GP sera to V2, Glycan and ADCC mediating epitopes by ELISA. FIG. 29G shows Epitope specific blocking activity of guinea pig sera from the indicated groups (GP502 and GP503) was measured by ELISA. FIG. 29H shows Epitope specific blocking activity of guinea pig sera from the indicated groups (GP502 and GP504) was measured by ELISA. FIG. 29I shows Epitope specific blocking activity of guinea pig sera from the indicated groups (GP502 and GP505) was measured by ELISA. FIG. 29J shows Epitope specific blocking activity of guinea pig sera from the indicated groups (GP502 and GP506) was measured by ELISA. FIG. 29K shows Epitope specific blocking activity of guinea pig sera from the indicated groups (GP504 and GP505) was measured by ELISA. FIG. 29L shows Epitope specific blocking activity of guinea pig sera from the indicated groups (GP505 and GP506) was measured by ELISA.

FIG. 30 shows Binding of guinea pig pre-bleed sera from the indicated groups (GP502-GP506) to gp120 protein was determined by indirect ELISA. Plates were coated with protein at 2 ug/ml and sera were tittered in 3 fold serial dilutions. Each titration was expressed as the log of area under the curve (Log AUC). Each symbol represents an individual animal within each group of six animals. Higher Log AUC represents greater binding to the test protein.

FIG. 31 shows Binding of guinea pig pre-bleed sera from the indicated groups (GP502-GP506) to gp140 protein was determined by indirect ELISA. Plates were coated with protein at 2 ug/ml and sera were tittered in 3 fold serial dilutions. Each titration was expressed as the log of area under the curve (Log AUC). Each symbol represents an individual animal within each group of six animals. Higher Log AUC represents greater binding to the test protein.

FIG. 32 shows Binding of guinea pig pre-bleed sera from the indicated groups (GP502-GP506) to V1V2 proteins was determined by indirect ELISA. Plates were coated with protein at 2 ug/ml and sera were tittered in 3 fold serial dilutions. Each titration was expressed as the log of area under the curve (Log AUC). Each symbol represents an individual animal within each group of six animals. Higher Log AUC represents greater binding to the test protein.

DETAILED DESCRIPTION OF THE INVENTION

Abbreviations and Definitions

Detailed descriptions of one or more embodiments are provided herein. It is to be understood, however, that the invention can be embodied in various forms. Therefore, specific details disclosed herein are not to be interpreted as limiting, but rather as a basis for the claims and as a representative basis for teaching one skilled in the art to employ the invention in any appropriate manner.

The singular forms “a”, “an” and “the” include plural reference unless the context clearly dictates otherwise. The use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and/or the specification can mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.”

Wherever any of the phrases “for example,” “such as,” “including” and the like are used herein, the phrase “and without limitation” is understood to follow unless explicitly stated otherwise. Similarly “an example,” “exemplary” and the like are understood to be non-limiting.

The term “substantially” allows for deviations from the descriptor that do not negatively impact the intended purpose. Descriptive terms are understood to be modified by the term “substantially” even if the word “substantially” is not explicitly recited.

The terms “comprising” and “including” and “having” and “involving” (and similarly “comprises”, “includes,” “has,” and “involves”) and the like are used interchangeably and have the same meaning. Specifically, each of the terms is defined consistent with the common United States patent law definition of “comprising” and is therefore interpreted to be an open term meaning “at least the following,” and is also interpreted not to exclude additional features, limitations, aspects, etc. Thus, for example, “a process involving steps a, b, and c” means that the process includes at least steps a, b and c. Wherever the terms “a” or “an” are used, “one or more” is understood, unless such interpretation is nonsensical in context.

As used herein the term “about” is used herein to mean approximately, roughly, around, or in the region of. When the term “about” is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term “about” is used herein to modify a numerical value above and below the stated value by a variance of 20 percent up or down (higher or lower).

In certain embodiment, the invention provides a composition comprising any one of the inventive proteins, wherein the composition comprises purified homogenously glycosylated protein. In certain embodiments, about 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 99.9% of the proteins in the composition are homogenously glycosylated. In certain embodiments, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 99.9% of the proteins in the composition are homogenously glycosylated. In certain embodiments, 70%-75%, 75.1%-80%, 80.1%-85%, 85.1%-90%, 90.1%-95%, 95.1%-99%, 96%-99%, 97%-99%, 98%-99% or 99.9% of the proteins in the composition are homogenously glycosylated.

Various methods of determining the glycosylation pattern on a peptide are known in the art. In certain embodiments, glycosylation pattern on the peptides and % homogeneity can be determined by Liquid chromatography—mass spectrometry (LC-MS, or alternatively HPLC-MS).

The immunogens can be formulated with appropriate carriers using standard techniques to yield compositions suitable for administration. The compositions can include an adjuvant, such as, for example, alum, poly IC, poly IC/LC, MF-59 or other squalene-based adjuvant, ASO1B or other liposomal based adjuvant suitable for protein immunization. Suitable vaccine strategies include without limitation, e.g., those described in the Examples that follow.

Nucleic acid sequences (e.g., DNA sequences) encoding the immunogens can also be administered to a subject (e.g., a human) under conditions such that the immunogen is expressed in vivo and BNAbs are produced. The DNA can be naked DNA with a potent promoter such as the CMV promoter as used in the pCMVr plasmid (Churchyard et al, PLoS One 6:e21225 (2011)) or as an insert in a vector, such as a rAdenoviral (Barouch, et al. Nature Med. 16: 319-23 (2010), recombinant mycobacterial (i.e., BCG or M smegmatis) (Yu et al. Clinical Vaccine Immunol. 14: 886-093 (2007); ibid 13: 1204-11 (2006), or recombinant vaccinia type of vector (Santra S. Nature Med. 16: 324-8 (2010)).

Immunogens of the invention, and nucleic acids (e.g., DNAs) encoding same, are suitable for use in generating an immune response (e.g., BNAbs) in a patient (e.g., a human patient) to HIV-1. The V3 N301, N332 peptide glycan can optimally be administered as a peptide-glycan formulated in a squalene based adjuvant such as MF 59, or GLA-SE (Alving et al, Current Opinion in Immunology 24:310 (2012)). The mode of administration of the immunogen, or encoding sequence, can vary with the immunogen to be administered, the patient and the effect sought, similarly, the dose administered. For example, the administration route is intramuscular or subcutaneous injection (intravenous and intraperitoneal can also be used). Additionally, the formulations can be administered via the intranasal route, or intrarectally or vaginally as a suppository-like vehicle. Optimum dosing regimens can be readily determined by one skilled in the art. The immunogens (and nucleic acids encoding same) are for use prophylactically, however, their administration to infected individuals can reduce viral load.

The invention includes the specific protein immunogens disclosed herein and nucleic acids comprising nucleotide sequences encoding same. The proteins can be expressed, for example, in 293T cells, 293F cells or CHO cells (Liao et al, Virology 353:268-82 (2006)).

In some embodiments the antigens are nucleic acids, including but not limited to mRNAs which could be modified and/or unmodified. See US Pub 20180028645A1, US Pub 20170369532, US Pub 20090286852, US Pub 20130111615, US Pub 20130197068, US Pub 20130261172, US Pub 20150038558, US Pub 20160032316, US Pub 20170043037, US Pub 20170327842, each content is incorporated by reference in its entirety.

In certain embodiments, where the composition comprises nucleic acids such as mRNA, whether modified or unmodified, the mRNAs could be formulated in lipid nanoparticles (LNPs). See US Pub 20180028645A1 and WO 2015/164674), where the content is incorporated by reference in its entirety. mRNAs delivered in LNP formulations have advantages over non-LNPs formulations. See US Pub 20180028645A1.

In some aspects the invention provides vectors comprising the nucleic acids of the invention. In some aspects, the invention provides a host cell, cell cultures or plurality of host cells comprising the nucleic acids of the invention.

Sequences/Clones

Described herein are nucleic and amino acids sequences of HIV-1 envelopes. The sequences for use as immunogens are in any suitable form. In certain embodiments, the described HIV-1 envelope sequences are gp160s. In certain embodiments, the described HIV-1 envelope sequences are gp120s. Other sequences, for example but not limited to stable SOSIP trimer designs, gp145s, gp140s, both cleaved and uncleaved, gp140 Envs with the deletion of the cleavage (C) site, fusion (F) and immunodominant (I) region in gp41—named as gp140ΔCFI (gp140CFI), gp140 Envs with the deletion of only the cleavage (C) site and fusion (F) domain—named as gp140ΔCF (gp140CF), gp140 Envs with the deletion of only the cleavage (C)—named gp140ΔC (gp140C) (See e.g. Liao et al. Virology 2006, 353, 268-282), gp150s, gp41s, which are readily derived from the nucleic acid and amino acid gp160 sequences. In certain embodiments the nucleic acid sequences are codon optimized for optimal expression in a host cell, for example a mammalian cell, a rBCG cell or any other suitable expression system.

An HIV-1 envelope has various structurally defined fragments/forms: gp160; gp140—including cleaved gp140 and uncleaved gp140 (gp140C), gp140CF, or gp140CFI; gp120 and gp41. A skilled artisan appreciates that these fragments/forms are defined not necessarily by their crystal structure, but by their design and bounds within the full length of the gp160 envelope. While the specific consecutive amino acid sequences of envelopes from different strains are different, the bounds and design of these forms are well known and characterized in the art.

For example, it is well known in the art that during its transport to the cell surface, the gp160 polypeptide is processed and proteolytically cleaved to gp120 and gp41 proteins. Cleavages of gp160 to gp120 and gp41 occurs at a conserved cleavage site “REKR.” See Chakrabarti et al. Journal of Virology vol. 76, pp. 5357-5368 (2002) see for example FIG. 1, and Second paragraph in the Introduction on p. 5357; Binley et al. Journal of Virology vol. 76, pp. 2606-2616 (2002) for example at Abstract; Gao et al. Journal of Virology vol. 79, pp. 1154-1163 (2005); Liao et al. Virology vol. 353(2): 268-282 (2006).

The role of the furin cleavage site is well understood both in terms of improving cleave efficiency, see Binley et al. supra, and eliminating cleavage, see Bosch and Pawlita, Virology 64 (5):2337-2344 (1990); Guo et al. Virology 174: 217-224 (1990); McCune et al. Cell 53:55-67 (1988); Liao et al. J Virol. Apr; 87(8):4185-201 (2013).

Likewise, the design of gp140 envelope forms is also well known in the art, along with the various specific changes which give rise to the gp140C (uncleaved envelope), gp140CF and gp140CFI forms. Envelope gp140 forms are designed by introducing a stop codon within the gp41 sequence. See Chakrabarti et al. at FIG. 1.

Envelope gp140C refers to a gp140 HIV-1 envelope design with a functional deletion of the cleavage (C) site, so that the gp140 envelope is not cleaved at the furin cleavage site. The specification describes cleaved and uncleaved forms, and various furin cleavage site modifications that prevent envelope cleavage are known in the art. In some embodiments of the gp140C form, two of the R residues in and near the furin cleavage site are changed to E, e.g., RRVVEREKR (SEQ ID NO: 180) is changed to ERVVEREKE (SEQ ID NO: 181), and is one example of an uncleaved gp140 form. Another example is the gp140C form which has the REKR site (SEQ ID NO: 182) changed to SEKS (SEQ ID NO: 183). See supra for references.

Envelope gp140CF refers to a gp140 HIV-1 envelope design with a deletion of the cleavage (C) site and fusion (F) region. Envelope gp140CFI refers to a gp140 HIV-1 envelope design with a deletion of the cleavage (C) site, fusion (F) and immunodominant (I) region in gp41. See Chakrabarti et al. Journal of Virology vol. 76, pp. 5357-5368 (2002) see for example FIG. 1, and Second paragraph in the Introduction on p. 5357; Binley et al. Journal of Virology vol. 76, pp. 2606-2616 (2002) for example at Abstract; Gao et al. Journal of Virology vol. 79, pp. 1154-1163 (2005); Liao et al. Virology vol. 353(2): 268-282 (2006).

In certain embodiments, the envelope design in accordance with the invention involves deletion of residues (e.g., 5-11, 5, 6, 7, 8, 9, 10, or 11 amino acids) at the N-terminus. For delta N-terminal design, amino acid residues ranging from 4 residues or even fewer to 14 residues or even more are deleted. These residues are between the maturation (signal peptide, for example ending with CXX, X can be any amino acid) and “VPVXXXX . . . ”. In certain embodiments, the invention comprises an immunogen, gp160, gp120 or gp140, without an N-terminal Herpes Simplex gD tag substituted for amino acids of the N-terminus of gp120, with an HIV leader sequence (or other leader sequence), and without the original about 4 to about 25, for example 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 amino acids of the N-terminus of the envelope (e.g. gp120). See WO2013/006688, e.g. at pages 10-12, the contents of which publication is hereby incorporated by reference in its entirety.

The general strategy of deletion of N-terminal amino acids of envelopes results in proteins, for example gp120s, expressed in mammalian cells that are primarily monomeric, as opposed to dimeric, and, therefore, solves the production and scalability problem of commercial gp120 Env vaccine production. In other embodiments, the amino acid deletions at the N-terminus result in increased immunogenicity of the envelopes.

In certain embodiments, the invention provides envelope sequences, amino acid sequences and the corresponding nucleic acids, and in which the V3 loop is substituted with the following V3 loop sequence TRPNNNTRKSIRIGPGQTFY ATGDIIGNIRQAH (SEO ID NO: 171). This substitution of the V3 loop reduced product cleavage and improves protein yield during recombinant protein production in CHO cells. Other strategies for eliminating cleavage during recombinant production can be used.

Within the sequences disclosed herein, the deltaN is deletion of amino acids (whatever number) immediately after signal peptide and up to the sequences VPV.

In some embodiments, the sequences include modification such that the furin cleavage sites are eliminated. Eliminates the site for furin because we change it in gp140C but we match the gp120s

Fixing the V3 loop to prevent cleavage during recombinant production—in some embodiments, taking the GPGR/S/K is made into GPGQ (SEQ ID NO: 179), and also the Ala after the R/S/K is made into T to prevent cleavage during recombinant production. In some embodiments, protease inhibitors also work, other mutations can also be made to reduce or eliminate the cleavage of the protein during recombinant production. See, for example, FIG. 17.

In certain aspects the invention comprises using immunogenic compositions wherein immunogens are delivered as DNA or RNA in suitable formulations. Various technologies which comprise using DNA or RNA, or can use complexes of nucleic acid molecules and other entities to be used in immunization. In certain embodiments, DNA or RNA is administered as nanoparticles consisting of low dose antigen-encoding DNA formulated with a block copolymer (amphiphilic block copolymer 704). See Cany et al., Journal of Hepatology 2011 vol. 54 j 115-121; Arnaoty et al., Chapter 17 in Yves Bigot (ed.), Mobile Genetic Elements: Protocols and Genomic Applications, Methods in Molecular Biology, vol. 859, pp 293-305 (2012); Arnaoty et al. (2013) Mol Genet Genomics. 2013 August; 288(7-8):347-63. Nanocarrier technologies called Nanotaxi® for immunogenic macromolecules (DNA, RNA, Protein) delivery are under development. See for example technologies developed by Incellart. In certain embodiments, the nucleic acids, for e.g. mRNAs encoding immunogens of the invention, are delivered by a lipid nanoparticle (LNP) technology. In non-limiting embodiments, the LNPs can comprise four different lipids that can self-assemble to 80-100 nm size particles.

In certain aspects the invention comprises using immunogenic compositions wherein immunogens are delivered as recombinant proteins. Various methods for production and purification of recombinant proteins suitable for use in immunization are known in the art. In certain embodiments recombinant proteins are produced in CHO cells.

The immunogenic envelopes can also be administered as a protein boost in combination with a variety of nucleic acid envelope primes (e.g., HIV −1 Envs delivered as DNA expressed in viral or bacterial vectors).

Dosing of proteins and nucleic acids can be readily determined by a skilled artisan. A single dose of nucleic acid can range from a few nanograms (ng) to a few micrograms (μg) or milligram of a single immunogenic nucleic acid. Recombinant protein dose can range from a few μg micrograms to a few hundred micrograms, or milligrams of a single immunogenic polypeptide.

Administration: The compositions can be formulated with appropriate carriers using known techniques to yield compositions suitable for various routes of administration. In certain embodiments the compositions are delivered via intramascular (IM), via subcutaneous, via intravenous, via nasal, via mucosal routes, or any other suitable route of immunization.

The compositions can be formulated with appropriate carriers and adjuvants using techniques to yield compositions suitable for immunization. The compositions can include an adjuvant, such as, for example but not limited to, alum, poly IC, MF-59 or other squalene-based adjuvant, ASO1B, or other liposomal based adjuvant suitable for protein or nucleic acid immunization. In certain embodiments, the adjuvant is GSK AS01E adjuvant containing MPL and QS21. This adjuvant has been shown by GSK to be as potent as the similar adjuvant AS01B but to be less reactogenic using HBsAg as vaccine antigen [Leroux-Roels et al., IABS Conference, Apr. 2013, 9]. In certain embodiments, TLR agonists are used as adjuvants. In other embodiment, adjuvants which break immune tolerance are included in the immunogenic compositions.

In certain embodiments, the compositions are formulated such that the immunogens are comprises in nanoparticles. In some embodiments, these are lipid nanoparticle immunogens. In some embodiments, these are liposomes comprising immunogens. In some embodiments these are lipid nanodiscs. The immunogens can be arranged as particulate, high-density array on liposomes or other particles, for example but not limited to nanoparticles. In non-limiting embodiment, the liposome comprises cholesterol, PC, PE, PA, or any combination thereof. See Alam et al. J Immunol. 2007 Apr. 1; 178(7):4424-35; Alam et al. J Virol. 2008 January; 82(1):115-25; Alam et al. Proc Natl Acad Sci USA. 2009 Dec. 1; 106(48):20234-9. doi: 10.1073/pnas.0908713106; Dennison et al. J Virol. 2009 October; 83(19):10211-23. doi: 10.1128/JVI.00571-09; Dennison et al. PLoS One. 2011; 6 (11):e27824. doi: 10.1371/journal.pone.0027824. In some embodiments, the lipid composition of lipid nanoparticle comprises cholesterol, POPC, sphingomyelin, or any combination thereof. In some embodiments, the lipids can comprise POPC, POPE, DMPA, cholesterol, or any combination thereof. In some embodiments, the ratio is POPC:POPE:DMPA:Cholesterol 45:25:20:1.33. In some embodiments, the protein to lipid ratio is about 1:3000. In some embodiments, the peptide to lipid ratio used provides 50-100 mer V3 peptide units per 100-200 nm lipid nanoparticle. In some embodiments the peptide:lipid ratio is 1:100. A skilled artisan can readily determine conditions and lipids to achieve different desired ratios.

In certain embodiments, the compositions and methods comprise any suitable agent or immune modulation which can modulate mechanisms of host immune tolerance and release of the induced antibodies. In non-limiting embodiments modulation includes PD-1 blockade; T regulatory cell depletion; anti-CD25 antibodies; CD40L hyperstimulation; anti-CTLA4 antibodies; soluble antigen administration, wherein the soluble antigen is designed such that the soluble agent eliminates B cells targeting dominant epitopes, or a combination thereof. In certain embodiments, an immunomodulatory agent is administered in at time and in an amount sufficient for transient modulation of the subject's immune response so as to induce an immune response which comprises broad neutralizing antibodies against HIV-1 envelope. Non-limiting examples of such agents is any one of the agents described herein: e.g. chloroquine (CQ), PTP1B Inhibitor-CAS 765317-72-4-Calbiochem or MSI 1436 clodronate or any other bisphosphonate; a Foxol inhibitor, e.g. 3443551Foxol Inhibitor, AS1842856-Calbiochem; Gleevac, anti-CD25 antibody, anti-CCR4 Ab, an agent which binds to a B cell receptor for a dominant HIV-1 envelope epitope, or any combination thereof. In non-limiting embodiments, the modulation includes administering an anti-CTLA4 antibody, OX-40 agonists, or a combination thereof. Non-limiting examples are ipilimumab and tremelimumab. In certain embodiments, the methods comprise administering a second immunomodulatory agent, wherein the second and first immunomodulatory agents are different.

One of skill in the art understands that the envelope glycoproteins referenced in various examples and figures can comprise a signal/leader sequence. It is well known in the art that HIV-I envelope glycoprotein is a secretory protein with a signal or leader peptide sequence that is removed during processing and recombinant expression (without removal of the signal peptide, the protein is not secreted). See for example Li et al. Control of expression, glycosylation, and secretion of HIV-I gp120 by homologous and heterologous signal sequences. Virology 204(1):266-78 (1994) (“Li et al. 1994”), at first paragraph, and Li et al. Effects of inefficient cleavage of the signal sequence of HIV-1 gp120 on its association with calnexin, folding, and intracellular transport. PNAS 93:9606-9611 (1996) (“Li et al. 1996”), at 9609. Any suitable signal sequence can be used. In some embodiments the leader sequence is the endogenous leader sequence. Most of the gp120 and gp160 amino acid sequences include the endogenous leader sequence. In other non-limiting examples the leaders sequence is human Tissue Plasminogen Activator (TPA) sequence, human CDS leader sequence (e.g. MPMGSLQPLATLYLLGMLVASVLA (SEO ID NO: 184). Most of the chimeric designs include CDS leader sequence. A skilled artisan appreciates that when used as immunogens, and for example when recombinantly produced, the amino acid sequences of these proteins do not comprise the leader peptide sequences.

TABLE 1
shows various combinations (sets) of immunogens
		Global
	Clade B	Set 6 (6
		Set2 (2			Set 5 (2	valent)			Set 7
		Valent)	Set 3 (5	Set 4 (5	valent)	To compare	Set 6a		fill out M
		Natural	Valent)	Valent)	Variants	with	Alternative	Set 6b	group
	Set1 (2 Valent)	strains	5	4	of Set 1	(Structural)	to Set 6	Alternative	coverage
	Structural	chosen	Natural	Natural	Vaccine	Str.Mos.M5	(Structural)	to Set 6	(Structural
Envelope Names	mosaics	serially	strains	strains	mosaics)	(Structural)	(X or XX)	(Structural)	Mosaic)
ADCC-StrMos.B.1 + 1.1	X					X		X	X
ADCC-StrMos.B.1 + 1.2	X					X
ADCC.StrNat.B.1		X	X	X
ADCC.StrNat.B.2		X	X	X
Str.Nat.B3			X	X
Str.Nat.B4			X	X
Str.Nat.B5			X
A244 (see WO/2013/006688,					X
which is incorporated by
reference in its entirety)
ADCC-StrMos-Modified.B.1 + 1.1						X
ADCC-StrMos-Modified.B.1 + 1.2						X
ADCC.StrMos.C.1 + 1.1						X	X	X	X
ADCC.StrMos.C.1 + 1.2						X	X
ADCC.StrMos.AE.1 + 1.1						X	XX	X	X
ADCC.StrMos.AE.1 + 1.2						X	XX
ADCC-StrMos.M.3 + 2.4									X
ADCC-StrMos.M.3 + 2.5									X

EXAMPLES

The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion. One skilled in the art will appreciate readily that the present invention is well adapted to carry out various embodiments of the invention. Changes therein and other uses which are encompassed within the spirit of the invention as defined by the scope of the claims will occur to those skilled in the art.

Examples are provided herein to facilitate a more complete understanding of the invention. The following examples illustrate the exemplary modes of making and practicing the invention. However, the scope of the invention is not limited to specific embodiments disclosed in these Examples, which are for purposes of illustration only, since alternative methods can be utilized to obtain similar results.

In the below examples and throughout the specification ADCC and structural mosaics are used interchangeably.

Example 1—ADCC Vaccine Design Strategies

Improving results of RV144 Foundations

• • Previous studies for example in Pollara et al. J Virol. 88(14):7715 (2014):
    • RV305: a boost of RV144 expanded the ADCC repertoire, and drove affinity maturation of ADCC-mediating Abs
    • C1 and V2 ADCC Abs can act synergistically: A32 and V2 antibodies have synergistic ADCC. HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities.
  • Previous studied for example Finzi et al. J Virol. 91(7): e02452-16 (2017):
    • These studies show uniqueness of CRF01_AE viruses in terms of ADCC susceptibility. And also showed S375HW induction of A32 C1 Ab ADCC sensitivity for clades B, C, and D. Importance of uniqueness of AE viruses in being susceptible to ADCC. Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses.
  • Bradley et al. Nat Commun 2017 8:15711 (2017) showed that:
    • a designed pentavalent AE that improved protection in NHPs;
    • Adding diversity to the CRF01 cocktail improves Ab mediated protection in NHPs. Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge.
  • Weissman et al. “Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination.” Nature, 2017; DOI: 10.1038/nature21428:
    • mRNAs are just as good or better than proteins in inducing anti-Env Abs
    • Next generation vaccines to induce ADCC Abs could be mRNAs, and we could compare within-clade to global panels of ADCC mosaics and natural strains

RV305 boosting of RV144 vaccinees after 6-8 years

• • Broadened the number of V2 epitopes recognized
  • New V2 ADCC epitopes recognized
  • Expanded the C1 ADCC clonal lineages
  • Increased ADCC breadth (against clades CRF01, B and C) and potency.

A32 and V2 antibodies have synergistic ADCC

HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities (see Pollara J . . . Ferrari G J Virol. 88(14):7715 (2014)):

• • ALVAC/AIDSVax vaccine induced (ADCC) via antibodies against the Env V2 (CH58 & CH59 entered on K169) and constant 1 (C1) regions
  • Prebinding with RV144 C1 Abs increased binding of V2 Ab CH58, suggesting binding of the C1 Ab induced a conformation change that increased V2 epitope accessibility
  • C1 and V2 antibodies combined increased ADCC: Increased the HIV-1 ADCC activity of V2 Ab CH58 at concentrations similar to that observed in plasma of RV144 vaccinee

For Vaccine Design: Without wishing to be bound by theory, the ADCC responses against natural variants can be more effective if the diversity of both of these epitopes were better represented in the vaccine. Without wishing to be bound by theory, the synergy that results from C1 region antibody binding can enhance access to the V2 epitope be mimicked in a vaccine, and improve the V2 epitope response.

Importance of uniqueness of AE viruses in being susceptible to ADCC

Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses (see Prevost J . . . Finzi A J Virol. 91(7): e02452-16 (2017)):

• • CD4-bound HIV Env is preferentially targeted by ADCC (Veillette J Virol. 2015 89:545). HIV has evolved to down-regulate CD4, and limit Env on the cell surface, consistent with evading ADCC.
  • HIV typically has a Ser at position 375 (ST375>90% of non-CRF01 viruses). 375 is in the “CD4 Phe 43 cavity” of Env, a CD4 contact region.
  • CRF01_AE has an H375, in 99% of viruses. S375H/W—>spontaneous sampling of an Env conformation closer to the CD4-bound state, and increased ADCC senstivity. The H375 enhances the exposure of the C1, cluster A (A32) antibody epitope. The A244 CRF01 RV144 vaccine may have enabled better targeting of the A32 epitope region. Concern: The CRF01 circulating virus in Thailand may be more susceptible to such ADCC antibodies.

For Vaccine Design: Without wishing to be bound by theory, CRF01 A244 RV144 strain can be included, that has the A32 epitope naturally more exposed, improve responses to this region. Without wishing to be bound by theory, the vaccine triggered response can translate to protection against other variants in a vaccine cocktail that spend less time in the CD4-bound like state.

Adding diversity to the CRF01 cocktail improves Ab mediated protection in NHPs

Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge (see Bradley T . . . Haynes B, Nat Commun 2017 8:15711 (2017)):

• • The two CRF01 strains used in RV144 (92TH023 and A244) are highly similar, and identical in the important V2 region.
  • A Pentavalent gp120 boost was designed to optimize the diversity of CRF01 V2 motifs.
  • 8 weekly low-dose intrarectal challenges with SHIV-1157(QNE)Y173H (subtype C tier 2, with V2 modifications).
  • Immunization of 9 rhesus macaques showed a difference (p=0.02 KM log rank).
  • ALVAC-AE+bivalent (B/E) 4×'s—only 1/9 uninfected at the week 8 challenge
  • ALVAC-AE+pentavalent (B/E/E/E/E)—5/9 uninfected
  • ALVAC-AE+pentavalent (B/E/E/E/E)—5/9 uninfected
  • Four immunological parameters predicted decreased infection risk: (1) plasma Ab binding to HIV-infected cells; (2) peak ADCC antibody titers; (3) NK cell-mediated ADCC; and (4) Ab-mediated activation of MIP-1β in NK cells.

Design of ADCC/Structural Mosaics

• • Considers all structural contacts of every amino acid in the structure. Start with CD4-bound structures that expose Ab epitopes of antibodies thought to be involved in protective ADCC responses: C1 and V2.
  • Optimize for breadth in silico, for coverage of sequence and conformational epitope diversity.
  • Using a genetic algorithm, recombines natural proteins to maximize 3 dimensional potential epitope coverage:
  • No sequential regions in the sequence spanning 8 amino acids are not found in nature.
  • No spheres are not found in nature.
  • Solves to generate proteins that should be able to yield the best coverage of spheres in a population.
  • Sets are complementary. They are solved simultaneously or serially; In some embodiments, these sets are serial. The first members can be used alone, while the second member is complementary but in certain embodiments, is not to be used alone. See also Ex 2A.
  • The full database is used—M group is enriched for B, C and CRF01.
  • Animal studies to resolve the fewest Envs to include in an polyvalent Env boost regimen.

Three mosaic sets have members that are “B-like”, “C-like” as “CRF01 like” as a consequence, but once a particular local variant is present, it doesn't need to be covered again

New ADCC Designs

• • Without being bound by theory, mRNAs can be just as good or better than proteins in inducing anti-Env Abs.
  • The new ADCC designs disclosed herein co-optimize vaccine coverage of CD4 bound gp120 including C1 and V2 epitopes. As the combination can result in ADCC synergy, and Abs against both targets would require breadth.
  • Structural mosaics were used as a foundation for this design, working from the new CD4-bound structure having PDB accession No. 5VN3, and considering just the gp120 monomer, the vaccine delivery form.
  • Designs under current development:
  • Previously designed V2 C Glade pentavalent, with or without CRF01 A244 “trigger”
  • B Glade optimized for Merlin Robb's testing:
    • Bivalent: 2 structural mosaics, vs 2 best naturals for epitope coverage
    • Bivalent: 2 structural mosaic above, but modified to capture V2 sensitivity signatures
    • Pentavalent: 5 best natural B Glade, serial design
    • Pentavlent: 4 best natural B Glade, with CRF01 A244 “trigger”
  • Global mosaics: 3 valent is included in both of the other two:
    • 3 valent: Best mosaics for B, C, and CRF01 (CRF01 mosaic can be a surrogate for A244)
    • 6 valent: Best 2 structural mosaics for B, C, and CRF01
    • 5 valent: Best mosaics for B, C, and CRF01 fixed, and add two more complementary mosaics for optimal M group coverage

Vaccine Strategies and SHIV Challenge Experiments

• • Challenge: one B Glade SHIV that represent transmitted variants: (a) Compare all vaccines, 7 groups—too many so small animal immunogenicity; (b) Immunogenicity vs protection: this would be staged—only challenge using vaccine that gives the best response.
  • take best B Glade option, and the best global options and test with three challenges, 2×3 groups, 6 total
  • C clade and CRF01 pentavlent: (a) 1 B clade SHIVs; (b) 1 CRF01; (c) 1 C clade

Example 2: ADCC Vaccine Design

			B.tbl	B.tbl	C.tbl	C.tbl	01.tbl	01.tbl	others	others
	Clade	Valency	B-Ooff	B-1off	C-0off	C-1off	01-0off	01-1off	0off	1off
Vaccine-2B.StrMos.1 + 1	B	2	0.5093	0.7735	0.3085	0.5603	0.2894	0.5318	0.3281	0.5801
Vaccine-2C.StrMos.1 + 1	C	2	0.2868	0.5527	0.5157	0.7675	0.3061	0.5586	0.4249	0.6787
Vaccine-2CRF01.StrMos.1 + 1	CRF01	2	0.2512	0.5052	0.2795	0.5385	0.6088	0.8561	0.2823	0.5431
Vaccine-MosB.C.CRF01.best1	M	3	0.4793	07587	0.4785	0.7523	0.5656	0.8292	0.4419	0.7195
Vaccine-StrMosM.3	M	3	0.4904	0.7632	0.4854	0.7509	0.5644	0.8241	0.4523	0.7231
Vaccine-StrMosM.5	M	5	0.5266	0.7901	0.5532	0.7977	0.5716	0.8280	0.5105	0.7583
Vaccine-MosB.C.CRF01.best1 + 2	M	5	0.5300	0.7891	0.5463	0.7946	0.5877	0.8426	0.5126	0.7658
Vaccine-StrNat.Bpenta	B	5	0.5437	0.8051	0.3380	0.6104	0.3256	0.5877	0.3560	0.6240
Vaccine-StrNat. B4	B	4	0.5212	0.7897	0.3246	0.5967	0.3013	0.5611	0.3390	0.6062
Vaccine-StrNat. B3	B	3	0.4945	0.7658	0.3022	0.5727	0.2878	0.5327	0.3181	0.7645
Vaccine-StrNat. B2	B	2	0.4567	0.7265	0.2865	0.5366	0.2587	0.5053	0.2991	0.7365
Vaccine-StrNat. B1	B	1	0.3835	0.6614	0.2241	0.4716	0.1917	0.4322	0.2383	0.4907
Vaccine-V2Nat.Cpenta	C	5	0.2980	0.5873	0.S242	0.7835	0.3252	0.5987	0.4383	0.7045
Vaccine-SouthAfrica	C	3	0.2719	0.5490	0.4499	0.7223	0.2884	0.5512	0.3829	0.6531
Vaccine-1B.4CRF01.penta	CRF01 + B	5	0.9781	0.6816	0.3232	0.6104	0.6071	0.8605	0.3387	0.6284
Vaccine-RV144	CRF01 + B	3	0.3817	0.5881	0.2777	0.5055	0.4699	0.7170	0.2850	0.5164
Vaccine-Mos2B.2C.2CRF01.best1 + 1	M	6	0.5392	0.8016	0.5539	0.7992	0.6314	0.8708	0.5083	0.7665

The mosaic envelopes are designed using the same strategy to insert hypervariable regions designed to be used for the original structural mosaics, as those full Env proteins were highly biologically active, but not the same inserts. In that similar context they worked well. The same guiding principles for hypervariable loop characteristics make sense here. In brief:

• 1) Inventors restricted themselves to Glade matched acute infection Env sequences, as hypervariable loops tend to be selected to shorter at transmission.
• 2) Inventors characterized all hypervariable regions, looked for short repeated pattern in hypervariable regions that were repeated based on search strings of varying length. Repeated motifs of 5 or 6 amino acids or longer are infrequent, and favored natural hypervariable regions that carried repeated motifs.
• 3) Inventors picked hypervariable stretches that were of modest length, with only one or two potential N-linked glycosylation sites. There were not picked to be extremely short, just on the smaller side of natural variation, and that were not highly negatively charged.
• 4) Inventors made the paired sets (1+1) distinctive so we can have some diversity in these regions.

One of skill in the art understands that these designs are called “ADCC” because they were optimized with what is known about ADCC functionalities and good epitopes from RV144 in mind, the label is to distinguish them from the other T cell mosaics, and the trimer structure-based designed mosaic that were created using Joe Sodroski's s early model structure. This does not mean that these proteins are not useful for other immune responses. In non-limiting they can elicit good T cell responses, and can be useful for augmenting breadth of gp120 directed bNAbs.

Clade B

Set 1: Synthesize 2: ADCC-StrMos.B.1 + 1.1 + ADCC- 2 valent
StrMos.B.1 + 1.2 Structural mosaics
Set 2: Synthesize 2: ADCC.StrNat.B.1 + ADCC.StrNat.B.2 2 valent
2 Natural strains chosen serially to maximize coverage
Set 3: Synthesize 3: Set 2 + 3 more, Str.Nat.B3, Str.Nat.B4, 5 valent
Str.Nat.B5. pentavalent 5 Natural strains, 3 additional added
serially to Set 2 to maximize coverage
Set 4: Str. Nat. B pentavalent (Set 3, but Str.Nat.B5 is 5 valent
replaced with A244 gp120) 4 Natural strains to present B
clade variation with A244 to trigger responses
Set 5: Synthesize 2:             2 valent

Modified versions of Set 1 are also contemplated. Without wishing to be bound by theory, we can enhance induction of V2 targeting antibodies by including external signatures, such as those in, a strategy to try as an alternative to the addition of A244.

Global

Vaccine-Mos 2B. 2C. 2CRF01 Best 1 + 1 (6 valent), To
compare with Vaccine Str.Mos.M5 (5 valent).
Set 6: Synthesize 4: 2 B + 2 C + 2 CRF01 structural mosaic 6 valent
Set 1: ADCC-StrMos.B.1 + 1.1 + ADCC-StrMos.B.1 + 1.2 +
Add: ADCC-StrMos.C.1 + 1.1 + ADCC-StrMos.C.1 + 1.2 +
ADCC-StrMos.AE.1 + 1.1 + ADCC-StrMos.AE.1 + 1.2
Subset alternatives with these same set 6 proteins:
6A. 2 C or 2 CRF01 can be used as a stand-alone pair if 2 valent
desired analogous to Set 1, but optimized for other clades: clade
[C.1 + 1.1 + C.1 + 1.2] or [AE.1 + 1.1 + AE.1 + 1.2] focused
6B. A trivalent combination of the best three can also be 3 valent
tested:
[B.1 + 1.1 + C.1 + 1.1 + AE.1 + 1]
Set 7: Synthesize 2: 5 valent: The best of the 3 clades, [B.1 +
1.1 + C.1+ 1.1 + AE.1 + 1] Set as fixed input, then solve the
two best complements to these to fill out M group coverage.

In some embodiments, we can compare Set 6 (the 3 best pairs for B, C, and CRF01, hexavalent), versus Set 6B (the single best for B, C and CRF01, trivalent), versus set 6B plus the two best M group complements to Set 6B, pentavalent).

Example 2A: Sequence of ADCC Vaccine Designs

Set 1:

B.ADCC-StrMos.1+1, coverage: 0.509261

Note These are serial, 1+1.1 is the best single gp120 for the B Glade and can be used alone, and 1+1.2 is its best complement, both designed to maximize coverage while maintaining “real” and common structural spheres throughout the monomer.

ADCC-StrMos.B.1+1.1 (SEQ ID NO: 135)
MRVKGIRKNYQHLWRWGTMLLGMLMICSAAEQLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPT
DPNPQEVVLENVTENFNMWKNNMVEQMHEDIISLWDQSLKPCVKLTPLCVTLNC KGEIKN
CSFNITTSIRDKVQKEYALFYKLDVVPI YRLISCNTSVITQACPKVSFEPIPIHYCAPAGFAILKCND
KKFNGTGOCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSENFTNNAKTIIVQLNESVEINCTRPNNNTRKS
IHIGPGRAFYATGDIIGDIRQAHCNISREKWNNTLKQIVKKLREQFGNKTIVFNQSSGGDPEIVMHSFNCGGEFFY
CNTTQLFNSTW NDTITLPCRIKQIINMWQEVGKAMYAPPIRGQIRCSSNITGLLLTRDGG
ETFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPTKAKRRWQREKRV
V1 B acute Con SC31   (SEQ ID NO: 136)
V2 B acute Con 9077   (SEQ ID NO: 137)
V4 B acute Con TT31P   (SEQ ID NO: 138)
V5 B acute Con 6247   (SEQ ID NO: 139)
ADCC-StrMos.B.1+1.2 (SEQ ID NO: 140)
MKVKGIRKNCQHLWRWGIMLLGMLMICSATEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEAHNVWATHACVPT
DPNPQEIVLENVTENFNMWKNDMVEQMHEDIISLWDESLKPCVELTPLCVTLNC GGEMKNC
SFNVTTSIRDKMQKEYALFYSLDVVQI YRLINCNTSVITQACPKISFEPIPIHYCTPAGFAIKCNDKKFN
GSGPCKNVSTVQCTHGIKPVVSTQLLLNGSLAEEEIVIRSENFSDNAKTIIVQLNESVVINCTRPNNNTRKSISIG
PGRAFYATGDIIGNIRQAHCNLSRAEWNNTLRQIVTKLREQFKNKTIAFNHSSGGDPEIVMHTFNCGGEFFYCNST
QLFNSTW NGTITLQCRIKQIVNRWQEVGKAMYAPPISGQISCSSNITGLILTRDGG E
IFRPGGGNMKDNWRSELYKYKVVRIEPLGIAPTKARRRVVQREKRI
Which has coverage: 0.509261
V1 B acute Con 63215   (SEQ ID NO: 141)
V2 B acute Con Z85   (SEQ ID NO: 142)
V4 B acute Con 61792   (SEQ ID NO: 143)
V5 B acute Con SC20   (SEQ ID NO: 144)

Set 2 and Set 3: 2 or 5 valent B Glade structural mosaics:

B naturals, picked serially to be optimal using the structural mosaic code, to be used in series and combination. Either the first 2 can be used as bivalent pair, or all 5 as pentavalent, or the first 4 coupled with the CRF01 A244 as a pentavalent.

For the natural proteins, optimization was not done on the hypervariable loops, which are noted in red, and only gp120 was considered, gp41 is in blue. The red is needed for a full protein (pointing out that inventors did not use the hypervariable stretches in the optimization). In the black section, where no structure is available, inventors optimized across linear peptides.

ADCC-StrNat.B1--B.US.85.WCIPR.U69584 (SEQ ID NO: 185)
MKAKETRKNYQHLWRWGITLLGMLMICSAAEQLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWATHAC
VPTDPNPQEVVLENVTENFNMWKNNMVEQMHEDIISLWDQSLKPCVKLTPLCVTLNC
RGEIKNCSFNITTSIRDKVQKEYALFYKLDVVPI YRLISCNTSVITQACPK
VSFEPIPIHYCAPAGFAILKCNDKKFNGTGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEKEVVIRSENFTNN
AKTIIVQLDESVVINCTRPNNNTRKSIHIGPGRAFYTTGEIIGDIRQAHCTLNRTEWNNTLAKITEKLREQFG
NNITIVFNHSSGGDPEIVMHSFICGGEFFYCNTSQLFNSTWNSTW ERNITLPCRIKQIINLWQE
VGKAMYAPPIRGQIRCSSNITGLLLTRDGG EIFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPTK
AKRRVVQREKRAVGTIGAMFLGFLGAAGSTMGAASMTLTVQARLLLSGIVQQQNNLLRAIEAQQHLLQLTVWG
IKQLQARVLAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWSNKSLDEIWDNMTWMEWEREIDNYTNLIYTL
IEEYRNQQEKNEQALLELDKWASLWNWFNITNWLWYIKIFIMIVGGLVGLRIVFTVLSIVNRVRKGYSPLSFQ
TRLPTPRGPDRPEGIEEEGGERDRDRSGLLVDGFLALIWVDLRSLCLFSYHRLRDLLLIVARIVELLGRRGWE
VLKYWWNLLQYWSQELKNSAVSLLNATAIAVAEGTDRVIEVLQRACRAILHIPTRIRQGLERALL
ADCC-StrNat.B2--B.TT.93.QH0065_M.AF277060 (SEQ ID NO: 186)
MRVKETRRIWQHLWKWGTMLLGMLMIYSAAENLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWATHAC
VPTDPNPQEVVLGNVTENFNMWKNNMVEQMHEDVISLWDQSLKPCVKLTPLCVTLNC
KGEIKNCSFNITTTLRDKVQKAHALFYRLDVVPI YRLINCNTSVITQACPKVSFEPIPI
HFCTPAGFALLKCNNKKFNGTGPCTNVSTVQCTHGIKPVVSTQLLLNGSLAEEEVVIRSENFTDNAKTIIVQL
NDSVVINCTRPNNNTRKGITIGPGSVFYTGEIIGDIRQAHCNLSSAKWNNTLKQIVIKLREQFGNKTIVFNQS
SGGDPEIVLHSFNCGGEFFYCNTTQLFNSTW SKTITLPCRIKQIINMWQEVGKAMYAPPIR
GQIRCSSNITGLLLTRDGG EIFRPGGGNMRDNWRSELYKYKVVKIEPLGIAPTKAKRRVVQREKRA
VGTIGAMFLGFLGAAGSTMGAASITLTVQARLLLSGIVQQQNNLMRAIEAQQHMLQLTVWGIKQLQARVLAVE
RYLRDQQLLGIWGCSGKLICTTTVPWNASWSNKSVDYIWDNMTWMQWDREINNYTNYIYTLLEDAQNQQEKNE
QELLELDKWASLWNWFDITKWLWYIKIFIMIVGGLIGLRIVFAVLSIVNRVKQGYSPLSFQTHLPARREPDRP
EGIEGEGGEKDKDRSIRLVHGLLALIWDDLRSLCLFSYHHLRDLLLIVTRIVETLGRRGWEALKYWWNLLQYW
SQELKNSAVSLFDAIAIAVAEGTDRVIEWRRIFRAVLHIPTRIRQGLERALL
ADCC-StrNat.B3--B.CN.12.2039_2_13.KX693556 (SEQ ID NO: 187)
MRVKGIRKNCQHLWRWGTMLLGMLMICSAAENLWVTVYYGVPVWKEATTTLFCASDAKAYDTEAHNVWATHACVPT
DPNPQEVVLGNVTENFNMWKNDMVEQMHEDIISLWDQSLKPCVKLTPICVALNC
GGEMKNCSFNITTSIKTKVKDYALFYKLDIVPI YRLISCNTSVITQACPKISFEPIPIHYCTPAG
YALLKCNNKKFNGTGPCKNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSSNFTNNAKVIIVQLKEAVEINCTR
PNNNTRKSIHIGPGKAWYTTGEIIGNIRQAHCNISRTKWNNTLHQIVKKLRIQFGNKTIIFNQSAGGDPEIVVHSF
NCGGEFFYCNTSQLFNSTW NDTITLPCRIRQIVNMWQQVGKAMYAPPIAGQIRCSSNITG
VLLTRDGG ETFRPAGGDMRDNWRSELYKYKVVKIEPLGVAPTKAKRRVVQREKRAVGTLGAMFLGFL
GAAGSTMGAASITLTVQARQLLSGIVQQQRNLLRAIEAQQHLLQLTVWGIKQLQARVLAVERYLQDQQLLGIWGCS
GKLICTTTVPWNVSWSNKSLGEIWDNMTWMEWEREISNYTGQIYTLIEQSQNQQEKNELELLELDKWASLWNWFDI
SNWLWYIKIFIMIVGGLVGLRIIFAVLSIVNRVRQGYSPLSLQTRFPAQRGPGRPEGIEEEGGEQDRDRSERLVNG
FLTLFWVDLRSLCLFSYHSLRDLLLIVARIVELLGRRGWEALKYLWNLLQYWIQELKNSAVSLLNATAIAVAEGTD
RIIELAQRAFRAFLNIPTRIRQGLERALL
ADCC-StrNat.B4--B.US.05.1444_A22.HQ216584 (SEQ ID NO: 188)
MKVKGIRKNYQHLWRWGMMLLGMLMICSATEKLWVTVYYGVPVWRDATTTLFCASDAKAYETELHNVWATHACVPT
DPNPQEVVLGNVTENFNMWKNDMVEQMNEDIISLWDESLKPCVKLTPLCVTLNC PGE
IKNCSFNVTTGIRDKVRKDHALFYALDIVPI YRLVSCNTSVLTQACPKVFEPIPIHFCAPAGYAIIK
CNNKTFNGSGPCRNVSTVQCTHGIRPVVSTQLLLNGSLAEEEIVIRSANFSDNTKTIIVQLNEAVKINCTRPNNNT
RRSVHMGPGSAFYTTGGIIGDIRQAHCNISERDWNGALKQIVEKLGEQFQNKTIVFKQSSGGDPEWMHTFNCRGE
FFYCNTTKLFNSTW NGTITLQCRIKQIINMWQQVGKAMYAPPISGPISCSSNITGLILTRDGG
ETFRPGGGDMRDNWRSELYKYKVVKIEPIGVAPTKARRRVVQREKRAVGIGAFFLGFLGAAGSTMGAASITLT
VQARLLLSGIVQQQSNLLRAIEAQQHLLQLTVWGIKQLQARVLAVESYLRDQQLLGIWGCPGKLICTTNVPWNNSW
SKNKSYNQIWDNMTWMEWEREINNYTDYIYSLIEISQRQQEKNEQELLELDKWANLWTWFDITNWLWYIKIFIMIV
GGLIGLRIVFSVLSIVNRVRQGYSPLSFQTRLPTQRGPDRPEEIEEEGGERDRDRSSGLADGFLTLIWVDLRSLCL
FSYHRLRDLLLIVTRIVELLGRRGWEALKYWWNLLQYWSQELKSSAISLLNTIAIWAEGTDRIIEVAQRACGAIL
HIPRRIRQGFERILV
ADCC-StrNat.B5--B.BR.10.10BR_SP062.KT427799 (SEQ ID NO: 189)
MRAKETRKKYQHLWAWGTLLLGMLMICSATEQLWVTVYYGVPVWKDANTTLFCASDAKAYDTEVHNVWATHACVPT
DPSPQEIVLKNVTENFNMWKNNMVEQMHKDIISLWDESLKPCVKLTPLCVTLNC EGAIKNCS
FNATTGIQNKMKKEYALFYSLDIVQI YMLRSCNTSVITQACPKVTFEPIPIHYCAPAGFAILKCNDK
KFNGTGPCKNVSTVQCTHGIRPVVSTQLLLNGSLAEEEIIIRSENITNNAKTIIIQLNRSIEINCTRPNNNTRKSI
HMGWGRAFYATGDIIGDIRQAHCNLSGTKWNNTLYQIARKLREHFNNTIVFNQSSGGDPEIVMHTFNCGGEFFYCN
TTQLFNSTW NDTISLPCRIKQIINRWQEVGKAMYAPPIGGQIRCSSNITGILLTRDGG
ETFRPGGGNMKDNWRSELYKYKVVRIEPLGVAPTKAKRRVVQREKRAVTFGAFFLGFLGTAGSTMGAASITLTV
QARQLLSGIVQQQSNLLRAIEAQQRMLQLTVWGIKQLQARVLAVERYLKDQQLLGIWGCSGRLICTTAVPWNASWS
NKSLNEIWDNMTWMQWEREIDNYTNLIYTLIEESQYQQEKNEQELLELDKWASLWSWFNITNWL#VGGLVGLRIIF
AVLSIVKRVGQGYSPLSFQIRPPARRGPDRPEGIDEEGGERDRDRSNRLVDGFLALIWDDLRSLCLFSYHRLRDLL
SILTRIVELLGRRGWEALRYCWNLLKYWNQELKNGAVGLLGATAIAVAGGTDGIIEAVRGLCGAILNIPGRIRQGL
ERALL

Set 5:

Modified versions of Set 1, without wishing to be bound by theory, we can enhance induction of V2 targeting antibodies by including external signatures, such as those in, a strategy to try as an alternative to the addition of A244. These can be compared to Set 1 to see if they alter the antigenicity, and sensitivity to V2 antibodies like CH58 and CH59 first.

ADCC-StrMos-Modified.B.1+1.1  (SEQ
ID NO: 190)
MRVKGIRKNYQHLWRWGTMLLGMLMICSAAEQLWVTVYYGVPVWKEATTTLFCASDAKA DTEVHNVWATHACVPT
DPNPQEVVLENVTENFNMWKNNMVEQM ED ISLWDQSLKPCVKLTPLCVTLNC KGEIKN
CSFNVTTSI DKVQKEYALFYKLDVVPI YRLISCNTSVITQACPKVSFEPIPIHYC PAGFAILKCND
KKFNGTGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSENFTNNAKTIIVQLNESVEINCTRPNNNTRKS
IHIGPGRAFYATGDIIGDIRQAHCNISREKWNNTLKQIVKKLREQFGNKTIVFNQSSGGDPEIVMHSFNCGGEFFY
CNTTQLFNSTW NDTITLPCRIKQIINMWQEVGKAMYAPPIRGQIRCSSNITGLLLTRDGG
ETFRPGGGDMRDNWRSELYKYKWKIEPLGVAPTKAKRRWQREKRV
ADCC-StrMos-Modified.B.1+1.2 changes:   V16IV
K168K T219T   (SEQ ID NO: 191)
MKVKGIRKNCQHLWRWGIMLLGMLMICSATEKLWVTVYYGVPVWKEATTTLFCASDAKAoDTEAHNVWATHACVPT
DPNPQEIVLENVTENFNMWKNDMVEQM ED ISLWDESLKPCVELTPLCVTLNC GGEMKNC
SFNVTTSI DKMQKEYALFYSLDWQI YRLINCNTSVITQACPKISFEPIPIHYCTPAGFAIIKCNDKKFN
GSGPCKNVSTVQCTHGIKPVVSTQLLLNGSLAEEEIVIRSENFSDNAKTIIVQLNESVVINCTRPNNNTRKSISIG
PGRAFYATGDIIGNIRQAHCNLSRA WNNTLRQIVTKLREQFKNKTIAFNHSSGGDPEIVMHTFNCGGEFFYCNST
QLFNSTW NGTITLQCRIKQIVNRWQEVGKAMYAPPISGQISCSSNITGLILTRDGG E
IFRPGGGNMKDNWRSELYKYKVVRIEPLGIAPTKARRRVVQREKRI
Set 6:
ADCC-StrMos.C.1+1.1 + ADCC-StrMos.C.1+1.2
ADCC.StrMos.C.1+1.1 (SEQ ID NO: 192)
MRV-
RGILRNYQQWWIWGILGFWMLMICNVVGNLWVTVYYGVPVWKEAKTTLFCASDAKAYEKEVHNVWATHACVPT
DPNPQEMVLENVTENFNMWKNDMVDQMHEDIISLWDQSLKPCVKLTPLCVTLNC
KEEIKNCSFNATTELRDKKSKEYALFYRLDIVPL YRLINCNTSTITQACPKVSFDPIPIH
YCAPAGYAILKCNNKTFNGTGPCNNVSTVQCTHGIKPVVSTQLLLNGSLAEEEIIIRSENLTDNVKTIIVHLN
ESVEIVCTRPNNNTRKSIRIGPGQTFYATGDIIGDIRQAHCNISKGAWNETLQWVGKKLKEHFPNKTIKFNSS
SGGDLEITTHSFNCRGEFFYCNTSGLFNSTY NSTITLPCRIKQIINMWQEVGRAMYAPPIAGNITC
KSNITGLLLTRDGG ETFRPGGGDMRDNWRSELYKYKVVEIKPLGIAPTKAKRRVVEREKRV
V1 C ZA NA N Y Y NA 705010198acute  (SEQ ID NO: 193)
V2 C acute Con 703010054  (SEQ ID NO: 194)
V4 C ZA JN681249 N Y Y 3 So706 T10b 3acute  (SEQ ID NO: 195)
V5 C acute Con 703010193  (SEQ ID NO: 196)
ADCC.StrMos.C.1+1.2 (SEQ ID NO: 197)
MRVMGIQRNWPQWWIWGILGFWMIIICRVVGNLWVTVYYGVPVWREAKTTLFCASDAKAYEREVHNVWATHAC
VPTDPNPQELVLENVTENFNMWENDMVDQMHEDVISLWDQSLKPCVKLTPLCVTLKC NG
EIKNCSFNTTTELRDKKQKVSALFYRLDVVPL YILINCNTSAITQACPKVSFDPIPIHYCT
PAGYAILKCNNKTFNGTGPCHNVSTVQCTHGIKPVVSTQLLLNGSLTEGEIIIRSENLTNNAKTIIVHLNQSV
AIVCTRPGNNTRKSVRIGPGQAFYATGEIIGDIRQAYCNLTNWQETLKNVSKKLQERFNKTIRFAPSSGGDLE
ITTHSFNCGGEFFYCNTSSLFNSAY SSITIQCKIKQIINMWQGVGRAIYAPPIAGNITCNSNI
TGILLTRDGG SKNNTEEIFRPGGGNMKDNWRSELYRYKVVEIKPLGVAPTEAKRRVVEREKRA
V1 C acute Con CAP177  (SEQ ID NO: 198)
V2 C acute Con 703010010  (SEQ ID NO: 199)
V4 C acute Con 703010200  (SEQ ID NO: 200)
V5 C ZM EU166866 Y Y Y 2 249Macute  (SEQ ID NO: 201)
ADCC-StrMos.AE.1+1.1 + ADCC-StrMos.AE.1+1.2
ADCC.StrMos.AE.1+1.1 (SEQ ID NO: 202)
MRVKETQMNWPNLWKWGTLILGLVIICSASDNLWVTVYYGVPVWRDADTTLFCASDAKAHETEVHNVWATHAC
VPTDPNPQEIHLENVTENFNMWKNNMVEQMQEDVISLWDQSLKPCVKLTPLCVTLNC
IGNITDEVRNCSFNMTTELRDKKQKVHALFYKLDIVPI YRLINCNTSVIKQACPKISFDPI
PIHYCTPAGYAILKCNDKNFNGTGPCKNVSSVQCTHGIKPVVSTQLLLNGSLAEEEIIIRSENLTNNAKTIIV
HLNKSVEINCTRPSNNTRTSITIGPGQVFYRTGDIIGDIRKAYCEINGTKWNETLKQVAGKLKEHFNKTIIFQ
PPSGGDLEITMHHFNCRGEFFYCNTTKLFNSTW NGTIILPCRIKQIINMWQGVGQAMYAPPISGII
NCVSNITGILLTRDGGM ETFRPGGGNIKDNWRSELYKYKVVQIEPLGIAPTRAKRRVVEREKRV
V1 01 AE CN HM215386 Y Y Y NA BJOX025000 01 1acute
(SEQ ID NO: 203)
V2 01 AE TH NA N Y Y 2 254008P00Re lacute  (SEQ ID NO: 204)
V4 01 AE CN NA N Y Y NA BJMSM2249 13 21 2acute  (SEQ ID NO: 205)
V5 01 AE CN HM215394 N Y Y NA BJOX031000 02 2acute  (SEQ ID NO: 206)
ADCC.StrMos.AE.1+1.2 (SEQ ID NO: 207)
MRVKGTQMNWPNLWRWGTLILGLVIMCSASDNLWVTVYYGVPVWKDADTTLFCASDAKAHETEVHNIWATHAC
VPTDPNPQEIPLENVTENFNMWKNNMAEQMQEDVISLWDESLKPCVKLTPLCVTLHC
TDEVKNCSFNMTTEIRDKKQKVYALFYKLDIVQI YRLINCNTSVIKQACPKVSFD
PIPIHYCAPAGYALLKCNDKKFNGTGPCRNVSSVQCTHGIKPVVSTQLLLNGSLAEEEIIIRSENLTDNAKTI
IVHLNESVVINCTRPSNNVRISTRIGPGQVFYRTGEIIGDIRKAYCEINGTKWNKVLKEVTEKLKEHFNKTIIFQP
PSGGDLEITTHHFNCRGEFFYCNTTKLFNNTC CNNITLPCKIKQIINMWQGAGQAIYAPPISGSIKCVS
NITGIILTRDGG EIFRPGGGNMKDNWRNELYKYKVVQIEPLGVAPTKAKRRVVDREKRV
V1 01 AE CN HM215379 N Y Y NA BJOX018000 02 3
(SEQ ID NO: 208)
V2 01 AE CN NA N Y Y NA BJMSM2249 13 21 2acute  (SEQ ID NO: 209)
V4 01 AE CN HM215394 N Y Y NA BJOX031000 02 2acute  (SEQ ID NO: 210)
V5 01 AE CN HM215390 N Y Y NA BJOX028000 34 2acute  (SEQ ID NO: 211)

Set 7

Includes two complements to ADCC-StrMos.B.1+1.1 from Set 1 described herein, ADCC.StrMos.C.1+1.1 from Set 6 described herein, and ADCC.StrMos.AE.1+1.1 from Set 6 described herein. To these, add ADCC-StrMos.M.3+2.4 and ADCC-StrMos.M.3+2.5 to give an M group pentavalent.

ADCC-StrMos.M.3+2.4 (SEQ ID NO: 36)
MRVMGIQRNCQHLWRWGIMLLGMLMICNATDKLWVTVYYGVPVWRDAETTLFCASDAKGYDTEAHNVWATHAC
VPTDPSPQEIHLENVTEEFNMWKNNMVEQMHTDIISLWDQSLKPCVKLTPLCVTLDC R
EEIKNCSFNITTELRDKKKKVYSLFYKLDIVPI YMLINCNTSAITQACPKVTFEPIPIHFCAPAG
YAILKCKDKEFNGTGPCKNVSTVQCTHGIKPVVSTQLLLNGSLAEEEIMIRSENITNNAKIIIVQLNQSVVIN
CTRPGNNTRKSVRIGPGQTFYATGDIIGDIRQAHCNVSRIKWNTALQKVAKQLRKYFRNKTITFNQSSGGDPE
ITTHTFNCGGEFFYCNTSNLFNSTW STNITLQCRIKQIINMWQEVGRAIYAPPIEGNISC
SSNITGLLLTRDGGN EIFRPGGGNMRDNWRSELYKYKVVKIEPIGVAPTKARRRVVEREKRI
ADCC-StrMos.M.3+2.4 is mostly subtype A1 with a little bit of D.
V1 A1.KE.94.Q842 dl6.AF407162  (SEQ ID NO: 212)
V2 A1.CM.08.886 24.KP718928  (SEQ ID NO: 213)
V4 CD.KE.x.BK184 W6M ENV D2.DQ208491  (SEQ ID NO: 214)
V5 A1.KE.06.06KECst 005.FJ623481  (SEQ ID NO: 215)
ADCC-StrMos.M.3+2.5 (SEQ ID NO: 37)
MKVKGIQRNWPQWWIWGILGFWMLMICNVGGNLWVTVYYGVPVWREANTTLFCASDAKAYDTEVHNIWATHAC
VPTDPNPQEIVLGNVTENFNMWKNNMVDQMHEDVISLWDESLKPCVKLTPLCVTLEC
EGEIKNCSFNTTTEIRDKKKRAYALFYRPDVVPL YILINCNSSTITQACPKVSFEPI
PIHYCTPAGFALLKCNNKTFNGSGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEIVIRSENFTDNAKTIIV
QLNESVEINCTRPNNNTRKSIRIGPGQAFYATGEIIGNIRQAYCNINESLWNETLYKVSEKLKEYFNTTIEFQ
QPAGGDLEITTHSFNCRGEFFYCNTTKLFNGTY HSNITLPCKIKQIINMWQGVGRAMYAPPIA
GNITCISNITGLILTRDGG EIFRPGGGNMKDNWRSELYKYKVVEIKPLGLAPTEAKRRVVEREKRA
ADCC-StrMos.M.3+2.5 is a subtype B/C recombinant.
V1 B.BR.03.03BR1020.JN692445  (SEQ ID NO: 216)
V2 C.ZA.98.DU123 6.DQ411850  (SEQ ID NO: 217)
V4 C.BW.98.98BWMC134.AF443077  (SEQ ID NO: 218)
V5 C acute Con 089  (SEQ ID NO: 219)

Example 3: Animal Studies

Table 1 shows several different sets of immunogens based on different designs and combinations of envelopes. The immunological properties of these sets will be tested in various animal studies including mouse models, guinea pigs, non-human primates, or any other suitable model. These animal studies will be designed to test overall immune response, type of antibodies induced, durability of the induced immune response, and can include challenge with SIV or SHIV virus of a desired HIV-1 Glade to determine whether the immune response provides protection.

In non-limiting embodiments, the parameters analyzed in these studies are as described in Bradley et al (2017). In a non-limiting example, four immunological parameters predicted decreased infection risk: plasma Ab binding to HIV-infected cells; peak ADCC antibody titers; NK cell-mediated ADCC; Ab-mediated activation of MIP-1β in NK cells.

Any other suitable assay or correlates can be used to analyze the immune responses induced by the different sets of immunogens and the determine if the sets induce protective responses to SIV and SHIV challenge. Non-limiting examples correlates which can be analyzed include without limitation: antibody responses to C1C2 epitopes of the HIV-1 envelope, antibodies responses to V2 epitopes, antibody responses to V3 epitopes, alpha4 beta7 binding, ADCC activity, binding responses to virus infected cells (can also be used as proxy for ADCC activity), etc. Without limitation, antibody responses analyses include analyses for neutralizing and non-neutralizing antibodies, magnitude, durability, types, etc. of the induced antibody responses. Analyses can be done on any suitable sample, including without limitation plasma, serum, blood, urine, mucosal samples, etc.

Animal studies will be followed up by human clinical trials.

Example 4: Comparison of Combinations of ADCC Structural Mosaic Envs with Natural Envs for Induction of Env Binding Antibodies—Guinea Pig Studies

This example described a guinea pig study testing the following immunogens in Groups 502-506 (See also FIGS. 18, 19-35). All groups were adjuvanated with Rehydragel (MHRP autoclaved @ 5 mg/ml). Every individual protein was administered at a 100 ug dose at three week intervals. Postbleeds were collected two weeks after each immunization.

GP502: Immunization #1-5 with Immunogen:

ADCC-StrMos.B.1+1.1Δ11gp120/293F/Mon (100 ug), and

ADCC-StrMos.B.1+1.2Δ11gp120/293F/Mon (100 ug)

GP503: Immunization #1-5 with Immunogen:

ADCC-StrNat.B1Δ11gp120/293F/Mon (100 ug), and

ADCC-StrNat.B5Δ11gp120/293F/Mon (100 ug)

GP504: Immunization #1-5 with Immunogen:

ADCC-StrNat.B1Δ11 gp120/293F/Mon (100 ug)

ADCC-StrNat.B2Δ11gp120_CD5ss/293F/Mon (100 ug)

ADCC-StrNat.B3Δ11gp120/293F/Mon (100 ug)

ADCC-StrNat.B4Δ11gp120/293F/Mon (100 ug)

ADCC-StrNat.B5Δ11gp120/293F/Mon (100 ug).

GP505: Immunization #1-5 with Immunogen:

ADCC-StrMos.M.3+2.4/293F/Mon (100 ug)

ADCC-StrMos.M.3+2.5_TPAss/293F/Mon (100 ug).

GP506: Immunization #1-5 with Immunogen:

ADCC-StrMos.B.1+1.1Δ11gp120/293F/Mon (100 ug)

ADCC.StrMos.C.1+1.1Δ11gp120_TPAss/293F/Mon (100 ug)

ADCC.StrMos.AE.1+1.1Δ11gp120/293F/Mon (100 ug).

Preliminary data from this study, Figures XX-XX, show that in some embodiments, bivalent Glade B str. ADCC mosaics (Group 502) are better than Group 503, and not performing worse than other groups in binding or blocking assays; in some embodiments bivalent M str. Mos Group 505 are better or not performing worse than Group 506 (trivalent A, B, AE mos).

Additional neutralization assays testing neutralization of other viruses is in process.

Specificity of sera is epitope mapped by linear peptide arrays—experiments are in progress.

Comparison of immunogenicity of new Glade B ADCC bivalent mosaic group 1/group 502 with original “pentavalent Envs” of Bradley et al Nature Comm. 8: 15711, 2017 will be conducted.

Additional studies will include ADCP, binding to surface of virus infected cells.

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific substances and procedures described herein. Such equivalents are considered to be within the scope of this invention, and are covered by the following claims.

Claims

1. An immunogenic composition comprising a recombinant polypeptide ADCC-StrMos.B.1+1.1.DELTA.11gp120 (SEQ ID NO: 12), or a nucleic acid encoding said recombinant polypeptide.

2. The immunogenic composition of claim 1 wherein the composition further comprises a recombinant polypeptide ADCC-StrMos.B.1+1.2.DELTA.11gp120 (SEQ ID NO: 13), or a nucleic acid encoding said recombinant polypeptide.

3. The immunogenic composition of any one of claims 1 or 2 wherein the nucleic acid is a modified mRNA.

4. The immunogenic composition of claim 3 wherein the nucleic acid is operably linked to a promoter.

5. The immunogenic composition of any one of claims 1 or 2 further comprising an adjuvant.

6. The immunogenic composition of any one of claims 1 or 2 further comprising a carrier.

7. A method of inducing an immune response in a subject comprising administering to the subject an amount of the composition of any one of claims 1 or 2 in an amount sufficient to effect such induction.

8. The method of claim 7 further comprising administering an adjuvant.

9. The method of claim 7, wherein the composition is administered as a prime.

10. The method of claim 7, wherein the composition is administered as a boost.

11. A recombinant envelope ADCC-StrMos.B.1+1.1.DELTA.11gp120 (SEQ ID NO: 12) or a nucleic acid encoding the same.

12. A composition comprising the recombinant envelope of claim 11 and a carrier.

13. A nucleic acid encoding the recombinant envelope of claim 11.

14. A composition comprising the nucleic acid of claim 13 and a carrier.

15. A method of inducing an immune response in a subject comprising administering to the subject an amount of the composition of any one of claim 12 or 14 in an amount sufficient to effect such induction.